FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Shiro Kitamoto

Research Profile

Chemicals & Drugs

Living Beings

Procedures

Genetic Therapy

Disorders

Anatomy

Physiology

Transfection

Co-author Network

Publications

TOP 3
Toshihiro Ichiki; Aya Kamiharaguchi; Shiro Kitamoto; Hirohide Matsuura; Ryohei Miyazaki; Toru Hashimoto; Tomotake Tokunou; Kenji Sunagawa
Resveratrol attenuates angiotensin II-induced senescence of vascular smooth muscle cells.
Hirohide Matsuura; Ryohei Miyazaki; Eriko Narabayashi; Toru Hashimoto; Toshihiro Ichiki; Jiro Ikeda; Shiro Kitamoto; Kotaro Takeda; Tomotake Tokunou; Kenji Sunagawa
Inhibition of prolyl hydroxylase domain-containing protein downregulates vascular angiotensin II type 1 receptor.
Kisho Ohtani; Kensuke Egashira; Ken-ichi Hiasa; Qingwei Zhao; Shiro Kitamoto; Minako Ishibashi; Makoto Usui; Shujiro Inoue; Yoshikazu Yonemitsu; Katsuo Sueishi; Masataka Sata; Masabumi Shibuya; Kenji Sunagawa
Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Shiro Kitamoto (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Toshihiro Ichiki; Aya Kamiharaguchi; Shiro Kitamoto; Hirohide Matsuura; Ryohei Miyazaki; Toru Hashimoto; Tomotake Tokunou; Kenji Sunagawa
Resveratrol attenuates angiotensin II-induced senescence of vascular smooth muscle cells.
Regulatory peptides 2012;177(1-3):35-9.
2011: Hirohide Matsuura; Ryohei Miyazaki; Eriko Narabayashi; Toru Hashimoto; Toshihiro Ichiki; Jiro Ikeda; Shiro Kitamoto; Kotaro Takeda; Tomotake Tokunou; Kenji Sunagawa
Inhibition of prolyl hydroxylase domain-containing protein downregulates vascular angiotensin II type 1 receptor.
Hypertension 2011;58(3):386-93.
2004: Kisho Ohtani; Kensuke Egashira; Ken-ichi Hiasa; Qingwei Zhao; Shiro Kitamoto; Minako Ishibashi; Makoto Usui; Shujiro Inoue; Yoshikazu Yonemitsu; Katsuo Sueishi; Masataka Sata; Masabumi Shibuya; Kenji Sunagawa
Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells.
Circulation 2004;110(16):2444-52.
2004: Akio Saiura; Masataka Sata; Ken-ichi Hiasa; Shiro Kitamoto; Miwa Washida; Kensuke Egashira; Ryozo Nagai; Makuuchi Masatoshi
Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(10):1886-90.
2004: Shiro Kitamoto; Kaku Nakano; Yasuhiko Hirouchi; Yoshiro Kohjimoto; Shunichi Kitajima; Makoto Usui; Shujiro Inoue; Kensuke Egashira
Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(8):1522-8.
2004: Kisho Ohtani; Makoto Usui; Kaku Nakano; Yoshiro Kohjimoto; Shunichi Kitajima; Yasuhiko Hirouchi; X-H Li; Shiro Kitamoto; Akira Takeshita; Kensuke Egashira
Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys.
Gene therapy 2004;11(16):1273-82.
2004: Ken-ichi Hiasa; Minako Ishibashi; Kisho Ohtani; Shujiro Inoue; Qingwei Zhao; Shiro Kitamoto; Masataka Sata; Toshihiro Ichiki; Akira Takeshita; Kensuke Egashira
Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization.
Circulation 2004;109(20):2454-61.
2004: Minako Ishibashi; Ken-ichi Hiasa; Qingwei Zhao; Shujiro Inoue; Kisho Ohtani; Shiro Kitamoto; Miyuki Tsuchihashi; Takeshi Sugaya; Israel F Charo; Shinobu Kura; Teruhisa Tsuzuki; Tatsuro Ishibashi; Akira Takeshita; Kensuke Egashira
Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling.
Circulation research 2004;94(9):1203-10.
2004: Ken-ichi Hiasa; Kensuke Egashira; Shiro Kitamoto; Minako Ishibashi; Shujiro Inoue; Weihua Ni; Qingwei Zhao; Shin Nagata; Makoto Katoh; Masataka Sata; Akira Takeshita
Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor.
Basic research in cardiology 2004;99(3):165-72.
2004: Shiro Kitamoto; Kensuke Egashira
Endothelial dysfunction and coronary atherosclerosis.
Current drug targets. Cardiovascular & haematological disorders 2004;4(1):13-22.
2004: Weihua Ni; Shiro Kitamoto; Minako Ishibashi; Makoto Usui; Shujiro Inoue; Ken-ichi Hiasa; Qingwei Zhao; Ken-ichi Nishida; Akira Takeshita; Kensuke Egashira
Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(3):534-9.
2004: Chu Kataoka; Kensuke Egashira; Minako Ishibashi; Shujiro Inoue; Weihua Ni; Ken-ichi Hiasa; Shiro Kitamoto; Makoto Usui; Akira Takeshita
Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis.
American journal of physiology. Heart and circulatory physiology 2004;286(2):H768-74.
2004: Shiro Kitamoto; Kensuke Egashira
[Anti-inflammatory effect of HMG-CoA reductase inhibitors].
Nihon rinsho. Japanese journal of clinical medicine 2004;62(1):172-9.
2003: Shiro Kitamoto; Kensuke Egashira
Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases.
Expert review of cardiovascular therapy 2003;1(3):393-400.
2003: Shiro Kitamoto; Kensuke Egashira
[The role of nitric oxide in ischemic heart disease].
Nihon rinsho. Japanese journal of clinical medicine 2003;61 Suppl 5():853-9.
2003: Shiro Kitamoto; Kensuke Egashira; Akira Takeshita
Stress and vascular responses: anti-inflammatory therapeutic strategy against atherosclerosis and restenosis after coronary intervention.
Journal of pharmacological sciences 2003;91(3):192-6.
2002: Shujiro Inoue; Kensuke Egashira; Weihua Ni; Shiro Kitamoto; Makoto Usui; Kisho Otani; Minako Ishibashi; Ken-ichi Hiasa; Ken-ichi Nishida; Akira Takeshita
Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice.
Circulation 2002;106(21):2700-6.
2002: Minako Ishibashi; Kensuke Egashira; Ken-ichi Hiasa; Shujiro Inoue; Weihua Ni; Qingwei Zhao; Makoto Usui; Shiro Kitamoto; Toshihiro Ichiki; Akira Takeshita
Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Hypertension 2002;40(5):687-93.
2002: Yasuhiro Ikeda; Yoshikazu Yonemitsu; Chu Kataoka; Shiro Kitamoto; Terutoshi Yamaoka; Ken-Ichi Nishida; Akira Takeshita; Kensuke Egashira; Katsuo Sueishi
Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats.
American journal of physiology. Heart and circulatory physiology 2002;283(5):H2021-8.
2002: Makoto Usui; Kensuke Egashira; Kisho Ohtani; Chu Kataoka; Minako Ishibashi; Ken-ichi Hiasa; Makoto Katoh; Qingwei Zhao; Shiro Kitamoto; Akira Takeshita
Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2002;16(13):1838-40.
2002: Qingwei Zhao; Kensuke Egashira; Shujiro Inoue; Makoto Usui; Shiro Kitamoto; Weihua Ni; Minako Ishibashi; Ken-ichi Hiasa Ki; Toshihiro Ichiki; Masabumi Shibuya; Akira Takeshita
Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis.
Circulation 2002;105(9):1110-5.
2002: Chu Kataoka; Kensuke Egashira; Shujiro Inoue; Masao Takemoto; Weihua Ni; Masamichi Koyanagi; Shiro Kitamoto; Makoto Usui; Kozo Kaibuchi; Hiroaki Shimokawa; Akira Takeshita
Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats.
Hypertension 2002;39(2):245-50.
2002: Shiro Kitamoto; Kensuke Egashira
Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease.
Journal of atherosclerosis and thrombosis 2002;9(6):261-5.
2001: Weihua Ni; Kensuke Egashira; Chu Kataoka; Shiro Kitamoto; Masamichi Koyanagi; Shujiro Inoue; Akira Takeshita
Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis.
Circulation research 2001;89(5):415-21.
2001: Makoto Katoh; Kensuke Egashira; Chu Kataoka; Makoto Usui; M Koyanagi; Shiro Kitamoto; Yasushi Ohmachi; Akira Takeshita; Hiroshi Narita
Regression by ACE inhibition of arteriosclerotic changes induced by chronic blockade of NO synthesis in rats.
American journal of physiology. Heart and circulatory physiology 2001;280(5):H2306-12.
2001: Weihua Ni; Kensuke Egashira; Shiro Kitamoto; Chu Kataoka; Masamichi Koyanagi; Shujiro Inoue; K Imaizumi; C Akiyama; Ken-Ichi Nishida; Akira Takeshita
New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice.
Circulation 2001;103(16):2096-101.
2000: Shiro Kitamoto; Kensuke Egashira; Chu Kataoka; Makoto Usui; Masamichi Koyanagi; Masao Takemoto; Akira Takeshita
Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II.
Journal of hypertension 2000;18(12):1795-800.
2000: Masamichi Koyanagi; Kensuke Egashira; Shiro Kitamoto; Weihua Ni; Hiroaki Shimokawa; Motohiro Takeya; T Yoshimura; Akira Takeshita
Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis.
Circulation 2000;102(18):2243-8.
2000: Kensuke Egashira; Masamichi Koyanagi; Shiro Kitamoto; Weihua Ni; Chu Kataoka; Ryuichi Morishita; Y Kaneda; C Akiyama; Ken-Ichi Nishida; Katsuo Sueishi; Akira Takeshita
Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(13):1974-8.
2000: Shiro Kitamoto; Kensuke Egashira; Chu Kataoka; Masamichi Koyanagi; Makoto Katoh; Hiroaki Shimokawa; Ryuichi Morishita; Y Kaneda; Katsuo Sueishi; Akira Takeshita
Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats.
Circulation 2000;102(7):806-12.
2000: Kensuke Egashira; Weihua Ni; Shujiro Inoue; Chu Kataoka; Shiro Kitamoto; Masamichi Koyanagi; Akira Takeshita
Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions.
Hypertension research : official journal of the Japanese Society of Hypertension 2000;23(4):353-8.
2000: Masamichi Koyanagi; Kensuke Egashira; Mayuko Kubo-Inoue; Makoto Usui; Shiro Kitamoto; H Tomita; Hiroaki Shimokawa; Akira Takeshita
Role of transforming growth factor-beta1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis.
Hypertension 2000;35(1 Pt 1):86-90.
1999: Makoto Usui; Kensuke Egashira; Shiro Kitamoto; Masamichi Koyanagi; Makoto Katoh; Chu Kataoka; Hiroaki Shimokawa; Akira Takeshita
Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats.
Hypertension 1999;34(4 Pt 1):546-51.